首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 62 毫秒
1.
 【摘要】 目的 观察重组人血管内皮抑素(YH-16)(商品名:恩度)联合多西紫杉醇+顺铂(DP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性,同时探讨血清血管内皮生长因子(VEGF)与DP方案疗效的相关性。方法 将67例Ⅳ期复治NSCLC患者按随机数字表法分为两组,试验组(32例)给予YH-16联合DP方案,对照组(35例)单用DP方案,分别接受至少2个周期的化疗。观察两组患者的有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)和安全性,并检测两组患者治疗前后VEGF的水平。结果 试验组和对照组的RR分别为43.8 %(14/32)和25.7 %(9/35)(χ2=3.864,P<0.05),CBR分别为78.1 %(25/32)和54.3 %(19/35)(χ2=4.214,P<0.05),中位TTP分别为225 d和135 d(t=5.284,P<0.05),两组患者治疗后QOL评分均有所提高,以试验组提高较明显(t=15.043,P<0.001),两组治疗后血清VEGF的水平均有不同程度的下降,以试验组下降较显著(P<0.05)。两组在血液学及非血液学毒性方面,中、重度不良反应的发生率差异均无统计学意义。结论 YH-16联合DP方案治疗晚期NSCLC安全有效,耐受性好;VEGF可能是预测化疗联合抗血管生成治疗疗效的一个较好指标。  相似文献   

2.
 【摘要】 目的 评价重组人血管内皮抑制素(商品名:恩度)联合吉西他滨加顺铂(GP)方案治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性。方法 采用非随机同期对照的方法,以接受重组人血管内皮抑制素联合化疗的NSCLC患者32例为试验组,单纯GP方案化疗者40例为对照组。比较两组有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)及安全性。结果 试验组和对照组的总RR分别为40.6 %(13/32)和 20.0 %(8/40),差异无统计学意义(χ2=3.66,P=0.07),总 CBR分别为68.8 %(22 /32)和42.5 %(17/40),差异有统计学意义(χ2=4.93,P=0.034),总的中位TTP分别为 5.2个月和3.9个月,差异有统计学意义(P=0.042)。试验组与对照组不良反应的发生率差异无统计学意义(P>0.05)。结论 重组人血管内皮抑制素联合 GP方案能明显提高晚期NSCLC的RR、CBR及中位TTP,安全性好,具有较好的临床应用前景。  相似文献   

3.
目的 观察重组人血管内皮抑素(YH-16)(商品名:恩度)联合多西紫杉醇+顺铂(DP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性,同时探讨血清血管内皮生长因子(VEGF)与DP方案疗效的相关性.方法 将67例Ⅳ期复治NSCLC患者按随机数字表法分为两组,试验组(32例)给予YH-16联合DP方案,对照组(35例)单用DP方案,分别接受至少2个周期的化疗.观察两组患者的有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)和安全性,并检测两组患者治疗前后VEGF的水平.结果 试验组和对照组的RR分别为43.8%(14/32)和25.7%(9/35)(x2=3.864,P<0.05),CBR分别为78.1%(25/32)和54.3%(19/35)(x2=4.214,P<0.05),中位TTP分别为225 d和135 d(f=5.284,P<0.05),两组患者治疗后QOL评分均有所提高,以试验组提高较明显(t=15.043,P<0.001),两组治疗后血清VEGF的水平均有不同程度的下降,以试验组下降较显著(P<0.05).两组在血液学及非血液学毒性方面,中、重度不良反应的发生率差异均无统计学意义.结论 YH-16联合DP方案治疗晚期NSCLC安全有效,耐受性好;VEGF可能是预测化疗联合抗血管生成治疗疗效的一个较好指标.  相似文献   

4.
目的 观察重组人血管内皮抑素(YH-16)(商品名:恩度)联合多西紫杉醇+顺铂(DP方案)治疗晚期非小细胞肺癌(NSCLC)的近期疗效和安全性,同时探讨血清血管内皮生长因子(VEGF)与DP方案疗效的相关性.方法 将67例Ⅳ期复治NSCLC患者按随机数字表法分为两组,试验组(32例)给予YH-16联合DP方案,对照组(35例)单用DP方案,分别接受至少2个周期的化疗.观察两组患者的有效率(RR)、临床受益率(CBR)、肿瘤进展时间(TTP)、生活质量(QOL)和安全性,并检测两组患者治疗前后VEGF的水平.结果 试验组和对照组的RR分别为43.8%(14/32)和25.7%(9/35)(x2=3.864,P<0.05),CBR分别为78.1%(25/32)和54.3%(19/35)(x2=4.214,P<0.05),中位TTP分别为225 d和135 d(f=5.284,P<0.05),两组患者治疗后QOL评分均有所提高,以试验组提高较明显(t=15.043,P<0.001),两组治疗后血清VEGF的水平均有不同程度的下降,以试验组下降较显著(P<0.05).两组在血液学及非血液学毒性方面,中、重度不良反应的发生率差异均无统计学意义.结论 YH-16联合DP方案治疗晚期NSCLC安全有效,耐受性好;VEGF可能是预测化疗联合抗血管生成治疗疗效的一个较好指标.  相似文献   

5.
沙利度胺联合NP方案治疗晚期非小细胞肺癌的临床研究   总被引:2,自引:0,他引:2  
 目的 研究沙利度胺联合NP方案治疗晚期非小细胞肺癌(NSCLC)的疗效,观察患者治疗前后外周血中血管内皮生长因子(VEGF)、碱性成纤维细胞生长因子(bFGF)的变化。方法 经病理学或细胞学确诊的Ⅲ/Ⅳ期NSCLC的初治或未采用NP方案化疗的复治患者57例,随机分为治疗组(NP方案+沙利度胺)36例和对照组(NP方案)21例。采用酶联免疫吸附实验(ELISA)检测VEGF、bFGF的水平。结果 治疗组有效(RR=CR+PR)为44.4 %(16/36),临床受益(CBR)为77.8 %(28/36);对照组RR为23.8 %(5/21), CBR为42.9 %(9/21)。两组RR及CBR比较差异无统计学意义(P>0.05)。治疗组中位肿瘤进展时间(TTP)5.1 个月,对照组为 3.0个月,与对照组比较,治疗组中位TTP延长(P=0.05)。治疗组CBR的患者血清VEGF水平显著下降(P<0.05)。对照组CBR的患者治疗前后血清VEGF对比差异无统计学意义(P>0.05)。两组临床进展的患者治疗后血清VEGF水平均比治疗前升高(P<0.05)。两组CBR者治疗后血清bFGF均有所下降,但均无统计学意义(P>0.05)。两组临床进展的患者治疗后血清bFGF水平均比治疗前明显升高,差异有统计学意义(P<0.05)。结论 沙利度胺联合NP方案能显著延长晚期NSCLC患者中位TTP,提高患者的RR及CBR。沙利度胺联合NP方案具有协同作用,且不明显增加化疗的不良反应;根据血清VEGF水平可推测病情进展;VEGF和bFGF在NSCLC血管形成过程中具有协同作用;血清VEGF和bFGF水平可能作为NSCLC患者疗效及预后的预测指标。  相似文献   

6.
王蓉  王宇岭  王庆才 《中国肿瘤》2007,16(6):476-477
[目的]比较多西紫杉醇联合顺铂(DP)及长春瑞滨联合顺铂(NP)一线治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。[方法]67例经细胞学或病理确诊的NSCLC患者分别接受DP(34例)或NP方案(33例)化疗,观察两组缓解率(RR)、疾病进展时间(TTP)、中位生存时间(MST)和1年、2年生存率。[结果]DP组CRI例、PR14例、RR44.1%、TTP6.5个月、MST10.6个月.1年生存率47.1%,2年生存率23.5%。NP组无CR、PR10例、RR30.3%、TTP4.7个月、MST8.5个月。1年生存率33.3%,2年生存率12.1%。两组肿瘤缓解率差异有统计学意义(P=0.046)。不良反应两组相似,无统计学意义。[结论]多西紫杉醇联合顺铂方案一线治疗晚期非小细胞肺癌,肿瘤缓解率优于长春瑞滨联合顺铂,有较好的耐受性及较高的临床缓解率;但1年及2年生存率差异无显著性。  相似文献   

7.
 目的探讨长春瑞滨加顺铂(NP方案)联合COX-2抑制剂(塞来昔布)一线治疗晚期非小细胞肺癌(NSCLC)的临床疗效和不良反应,以及COX-2受体表达高低不同对患者预后的影响。方法入组晚期NSCLC初治患者,采用免疫组化方法检测其标本中COX-2受体是否为高表达(阳性)或低表达(阴性),随机分为试验组或对照组(各30例),分别给予塞来昔布400mg,2次/日联合NP方案化疗或单纯化疗,至少2周期。结果试验组与对照组的有效率(RR)分别为43.3%和40%,中位生存期(MST)分别为9.8和9.5月(P〉0.05),不良反应主要为恶心呕吐、骨髓抑制等,两组无显著差异;受体表达阳性组及阴性组RR分别为42.1%和40.9%(P〉0.05),MST为9.9和9.4月;在受体表达阳性患者中,联合组和单纯化疗组的RR分别为45%和38.9%,MST分别为10.1和9.6月(P〉0.05)。结论NP方案联合塞来昔布一线治疗晚期NSCLC较单纯化疗相比,未能显著增加疗效及生存期,不良反应相似;COX-2受体表达程度对预后影响有待进一步研究。  相似文献   

8.
目的:评价NP方案化疗的晚期NSCLC患者CIL与化疗疗效之间的关系。方法:对128例I-Ⅳ期NSCLC患者采用NP化疗方案:顺铂35mg/m^2,静脉滴注,第1,2天;长春瑞滨25mg/m^2,静脉滴注,第1,8天,每21天为1周期根据CIL程度进行分组:无CIL的患者为A组;轻度CIL(G I-Ⅱ)为B组;重度CIL(GⅢ-Ⅳ)为C组。主要研究目的为有效率(RR)、疾病控制率(DCR)和疾病进展时间(TTP)。结果:共有128倒患者入组。A、B、C三组RR率分别为30.8%,56.8%和71.4%,P=0.010,出现CIL的患者RR率明显增高。DCR率分别为61.5%,83.8%和92.9%,P=0.009,CIL患者DCR率也明显提高。中位TTP分别为150天(95%CI:91-209),189天(95%CI:181-197)和207天(95%CI:172-242),P=-0.009,CIL患者TTP明显延长。CIL持续至少10天的患者TFP延长明显,p=0.0213。轻度CIL伴ECOG0的患者TTP也明显延长,P=0.0412。结论:CIL与NP方案化疗的晚期NSCLC患者的RR和TTP有关,随CIL的出现患者RR率提高,TTP延长,尤其是轻度CIL伴ECOG0和CIL持续10天以上的患者。因此,CIL可以作为反映药物活性和预测化疗疗效的指标。  相似文献   

9.
目的 观察重组人血管内皮抑制素(恩度)联合含铂化疗方案治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法 选取69例晚期NSCLC患者,分为恩度联合化疗组(n=33)和单纯化疗组(n=36),两组化疗均采用含铂两药联合方案;恩度15mg加入生理盐水500ml静滴,每天1次,持续14天。观察两组的客观有效率(RR)、疾病控制率(DCR)、肿瘤进展时间(TTP)及不良反应。结果 治疗2个周期后恩度联合化疗组和单纯化疗组的RR分别为27.3%和19.4%(P>0.05),DCR分别为90.9%和86.1%(P>0.05)。治疗4个周期后,恩度联合化疗组和单纯化疗组的RR分别为13.0%和10.7%,差异无统计学意义(P>0.05);DCR分别为82.6%和50.0%,差异有统计学意义(P<0.05)。恩度联合化疗组与单纯化疗组的中位TTP分别为6.5个月和4.7个月,差异有统计学意义(P=0.02)。两组主要不良反应为恶心呕吐、乏力及骨髓抑制,骨髓抑制以白细胞、中性粒细胞减少为主。恩度联合化疗组窦性心动过速发生率高于单纯化疗组(P<0.05)。结论 恩度联合含铂方案化疗能显著提高晚期NSCLC的中位TTP及治疗4个周期的DCR,且安全性较好,具有较好的临床应用前景。  相似文献   

10.
Li N  Jin ZL  Liu ZJ  Wang J  Li K 《中华肿瘤杂志》2011,33(12):937-942
目的 观察重组人血管内皮抑制素注射液联合TP或NP方案治疗晚期非小细胞肺癌(NSCLC)的疗效和安全性,并探讨与治疗周期的关系.方法 经病理组织学和(或)细胞学检查确诊的25例Ⅲb~Ⅳ期NSCLC患者,采用重组人血管内皮抑制素注射液联合NP方案治疗21例,联合TP方案治疗4例,21 d为1个周期,观察患者的近期疗效、疾病进展时间(TTP)、1年生存率、中位生存时间(OS)、生活质量变化和不良反应.采用流式细胞术检测治疗前、后外周血循环活化血管内皮细胞(aCECs)的数量,并评价其与疗效和治疗周期的关系.结果 全组25例患者均可进行疗效和安全性评价,其中部分缓解(PR)5例(20.0%),稳定(SD)14例(56.0%),进展(PD)6例(24.0%),客观有效率(RR)为20.0%,临床受益率(CBR)为76.0%,中位TTP为8个月,中位OS为19个月.短周期治疗(周期<4个)14例,其中PR 2例,SD 6例,PD 6例,RR为14.3%;临床受益的8例患者的中位TTP为6个月,中位OS为18个月.长周期治疗(周期≥4个)11例,均为临床受益患者,其中PR3例,SD 8例,RR为27.3%,中位TTP为17个月,中位OS为26个月.短周期治疗临床受益者aCECs 平均上升(293±12)个/105,长周期治疗临床受益者平均下降( 243±181)个/105.治疗周期、TTP均与治疗前、后aCECS的数量变化呈正相关(r=0.970,P=0.001;r=0.829,P=0.042).全组生活质量改善12例,稳定10例,下降3例.全组患者的常见不良反应为血液和胃肠道不良反应,均不影响继续用药,长周期组和短周期组患者3~4度不良反应的发生率差异无统计学意义.结论 重组人血管内皮抑制素注射液联合TP或NP方案治疗晚期NSCLC能显著提高远期疗效,长周期治疗的患者TTP和OS均较短周期者延长,且长周期治疗并不增加不良反应的发生率.aCECs是较好的预测NSCLC疗效的指标.  相似文献   

11.
Tobacco, alcohol, diet, occupation, and carcinoma of the esophagus   总被引:5,自引:0,他引:5  
Information on occupation, smoking, food and beverage consumption, and medical history were compared between 275 incident cases of carcinoma of the esophagus and 275 neighborhood controls who were matched to the cases on age (within 5 years), race, and sex. Tobacco use, mainly cigarette smoking, was a significant risk factor for carcinoma of the esophagus. Ex-smokers of cigarettes showed a reduced risk relative to those who continued to smoke, and current smokers of two or more packs per day displayed a higher risk than those who smoked less. Alcohol consumption was another significant risk factor for carcinoma of the esophagus; there was a highly significant trend with average daily dose of ethanol. Relative to controls, cases also consumed significantly more fried bacon or ham, less fresh fruits and raw vegetables, and were more likely to prefer white than whole grain bread. Finally, there was a significant association between carcinoma of the esophagus and long-term occupational exposure to metal dust; this association was largely confined to the lower one-third section of the esophagus.  相似文献   

12.
Fat, fiber, fruits, vegetables, and risk of colorectal adenomas   总被引:5,自引:0,他引:5  
A case-control study was conducted at the National Naval Medical Center (Maryland, USA) from 1994 to 1996 to investigate the possible association between dietary factors and colorectal adenomas. Cases (n = 239) were subjects diagnosed with adenomas (146 new and 93 recurrent) by sigmoidoscopy or colonoscopy. Those with no evidence of adenomas found by sigmoidoscopy were recruited as controls (n = 228). Dietary variables, assessed by a 100-item food frequency questionnaire, were analyzed by the logistic regression model, which was adjusted for age, gender and total energy intake. Variables of fat intake were further adjusted for red meat intake. An increased risk of 7% [odds ratio (OR): 1.07; 95% confidence interval (95% CI): 0.94-1.22] per 5% energy/day from total fat was observed. Every additional 5% unit of oleic acid intake/day significantly increased the adenoma risk by 115% (OR: 2.15; 95% CI: 1.05-4.39). Red meat fat increased the risk by 20% (OR: 1.20; 95% CI: 0.71-2.04), and white meat fat decreased the risk by 67% (OR: 0.33; 95% CI: 0.19-0.95) for every additional 5% unit of respective intake/day. Risk decreased by 41% (OR: 0.59; 95% CI: 0.41-0.86) for every additional 5% unit of fiber intake/day. Vegetable [OR per 100 g of vegetable intake/day: 0.83, 95% CI: 0.67-1.04] and fruit (OR per 100 g of fruit intake/day: 0.92, 95% CI: 0.82-1.03) intake showed an inverse association, and the results are suggestive of an association with the risk for adenomas. In conclusion, a strong positive association between oleic acid intake and colorectal adenoma risk was observed. This is likely to be an indicator of "unhealthy" food (meat, dairy, margarine, mayonnaise, sweet baked food) consumption in this population. Increased intake of dietary fiber was associated with a moderately decreased risk of adenomas.  相似文献   

13.
BackgroundThe incidence of the T- and B-cell CLs has been well documented, but information pertaining to racial incidence by age, and by burden of disease (stage) have not been extensively documented.Materials and MethodsThe SEER 2004-2008 public use database was investigated. The relative incidence of CL in different races and age groups was examined. Univariate and multivariate stepwise logistic regression was performed for the likelihood of presenting at a higher stage.ResultsOf 4496 patients diagnosed with CL between 2004 and 2008; 1713 patients were diagnosed with MF, 1518 with non-MF cutaneous T-cell lymphoma, and 1265 patients with cutaneous B-cell lymphoma. For MF, there was a trend for females to be less likely to present with a higher T-stage (T3-T4) than males (odds ratio [OR], 0.73) on multivariate analysis (P = .06). For race, AA had a significantly increased risk of presenting with higher T-stage (T3-T4) MF (OR, 1.72) on multivariate analysis (P = .02), compared with white patients. For white, AA, Asian/Pacific Islander, and Native American/other/unknown, the mean age at diagnosis was 59.2, 51.5, 51.3, and 53.8. These groups presented at a significantly different age than white (P = .0001, 0.0001, and 0.0006).ConclusionNonwhite racial groups present with MF at an earlier age compared with white, and AA have increased risk of presenting with higher T-stage compared with white. These findings have significant implications regarding need for earlier diagnosis and understanding the reasons for racial disparity in age and stage of presentation.  相似文献   

14.
The in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution method in A7 medium. The MIC(50) and MIC(90) of the tested agents after 24 h of incubation were as follows: tetracycline, 0.5 and 2.0 μg/ml; doxycycline, 0.125 and 0.25 μg/ml; erythromycin, 2.0 and 8.0 μg/ml; roxithromycin, 2.0 and 4.0 μg/ml; clarithromycin, 0.25 and 1.0 μg/ml; azithromycin, 2.0 and 4.0 μg/ml; levofloxacin, 1.0 and 2.0 μg/ml; and moxifloxacin, 0.5 and 0.5 μg/ml, respectively. The MIC values after 24 h and 48 h incubation differed by no more than one dilution for all the agents with the exception of doxycycline (two dilution difference for MIC(90)). Overall, moxifloxacin was the most active agent in vitro against U. urealyticum, with the narrowest difference between MIC and MBC values, followed closely by levofloxacin. Clarithromycin was the most active macrolide.  相似文献   

15.
Abstract

The in vitro activity of tetracycline, doxycycline, erythromycin, roxithromycin, clarithromycin, azithromycin, levofloxacin and moxifloxacin was tested against 63 clinical isolates of Ureaplasma urealyticum. The minimal inhibitory concentrations (MICs) and the minimal bactericidal concentrations (MBCs) were determined by the broth microdilution method in A7 medium. The miC50 and miC90 of the tested agents after 24 h of incubation were as follows: Tetracycline, 0.5 and 2.0 μg/ml; doxycycline, 0.125 and 0.25 μg/ml; erythromycin, 2.0 and 8.0 μg/ml; roxithromycin, 2.0 and 4.0 μg/ml; clarithromycin, 0.25 and 1.0 μg/ml; azithromycin, 2.0 and 4.0 μg/ml; levofloxacin, 1.0 and 2.0 μg/ml; and moxifloxacin, 0.5 and 0.5 μg/ml, respectively. The MIC values after 24 h and 48 h incubation differed by no more than one dilution for all the agents with the exception of doxycycline (two dilution difference for MIC90). Overall, moxifloxacin was the most active agent in vitro against U. Urealyticum, with the narrowest difference between MIC and MBC values, followed closely by levofloxacin. Clarithromycin was the most active macrolide.  相似文献   

16.
17.
Triclosan has broad-spectrum anti-microbial activity against most gram-negative and gram-positive bacteria. It is widely used in personal care products, household items, medical devices, and clinical settings. Due to its extensive use, there is potential for humans in all age groups to receive life-time exposures to triclosan, and, indeed, triclosan has been detected in human tissues and the environment. Data gaps exist regarding the chronic dermal toxicity and carcinogenicity of triclosan, which is needed for the risk assessment of triclosan. The US Food and Drug Administration (FDA) nominated triclosan to the National Toxicology Program (NTP) for toxicological evaluations. Currently, the NTP is conducting several dermal toxicological studies to determine the carcinogenic potential of triclosan, evaluate its endocrine and developmental-reproductive effects, and investigate the potential UV-induced dermal formation of chlorinated phenols and dioxins of triclosan. This paper reviews data on the human exposure, environmental fate, efficacy of anti-microbial activity, absorption, distribution, metabolism and elimination, endocrine disrupting effects, and toxicity of triclosan.  相似文献   

18.
19.
Histologic characteristics of bladder cancer in Boston, USA, Manchester, UK, and Nagoya, Japan, were evaluated. In each of these areas broadly-based series of cases were assembled during a collaborative case-control study. The present analysis was based on 589 cases in Boston, 484 cases in Manchester, and 241 cases in Nagoya. A single pathologist reviewed a slide of the primary tumor without reference to identifying information or other data. The primary histologic type of nearly all tumors was transitional-cell, and there was little variation in the proportion of transitional-cell tumors among the study areas. Nor was there much variation in the distribution of histologic grade, the proportion of tumors showing submucosal invasion, or the proportion of tumors with a papillary surface. Age at diagnosis was strongly correlated with histologic grade. The proportion of grade III (most malignant) tumors was about twice as high among patients 80 years of age and over as among those aged less than 50. An apparent association between age and submucosal invasion was explained in large part by the relationships of histologic grade to submucosal invasion and to age. Other histologic features had only weak and inconsistent relations with age. None of the features evaluated showed consistent associations with history of cigarettesmoking or with sex.  相似文献   

20.
ObjectivesStudies of local stage prostate cancer survivors suggest that treatments carry risk of persistent impotence, incontinence, and bowel dysfunction. To examine impacts of cancer type and side effects on health-related quality of life (HRQoL) in long-term cancer survivorship, we evaluated 5-year follow-up of patients with prostate cancer and compared results with a matched group of male long-term survivors of other local-stage cancers.Materials and MethodsWe examined genitourinary, bowel and sexual symptoms, and general quality of life. Matched survivors of colorectal, lung, and bladder cancers were recruited via registries in 3 different regions in the United States. Patients were surveyed 3–5 years after diagnosis with the SF-12 and EPIC to evaluate general mental and physical health-related quality of life (HRQoL) and patient function and bother.ResultsWe analyzed responses from long-term prostate (n = 77) and bladder, colorectal, and lung cancer (n = 124) patients. In multivariate analysis, long-term local stage prostate cancer survivors had significantly higher SF-12 physical component scores but did not differ from long-term survivors of other cancers in terms of their SF-12 mental summary scores. Prostate survivors had similar mental, urinary, bowel, and sexual HRQoL compared to long-term survivors of other local stage cancers.ConclusionLong-term general and prostate-specific HRQoL was similar between local stage prostate and bladder, colorectal, and lung patients with cancer. Future research focusing on factors other than initial treatment and the cancer type per se may provide more meaningful information regarding factors that predict disparities on HRQoL among longer-term survivors of early stage male cancers.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号